[PHARMANIAGA BHD：非特许业务的需求增加，这主要是由于持续的Covid-19大流行导致个人防护设备的销售增加]
2Q20 vs 2Q19:
截至2020年6月30日的第二季度，集团的收入增加到6.46亿令吉，比去年同期的6.02亿令吉增长7.3％。这主要是由于非特许业务的需求增加所致，这主要是由于持续的Covid-19大流行导致个人防护设备的销售增加所致。因此，集团取得了1,400万令吉的税前利润（PBT），与去年同期相比增长了14.8％。因此，这季的税后盈利（PAT）增长3.7％至1,000万令吉，相比去年同期的900万令吉。
YTD20 vs YTD19：
这财政年度的头六个月，集团实现了15亿令吉的收入，而去年同期为14亿令吉。这是在非特许经营业务的强劲贡献的支持下实现的，这主要是由于应对Covid-19疫情而导致的个人防护设备销量增加。这使集团的PBT增长5.8％至4,500万令吉。因此，集团录得3,200万令吉的PAT，高于去年同期的2,900万令吉。
物流及分销部首六个月的PBT为3,700万令吉，较去年同期的1,900万令吉增加96％。这是由于非特许业务的贡献有所提高。
制造部公布了1300万令吉的PBT，其营业额为1.37亿令吉，这与政府医院的订购趋势相符。随着新产品的推出，该部门的前景仍然乐观。此外，发马将寻求进一步拓展海外市场，以及通过其合同制造业务提高产能利用率。
印尼部门录得200万令吉的赤字。
2Q20 vs 1Q20：
这季度的PAT为1000万令吉，上一季度为2200万令吉。
前景：
展望未来，发马将继续致力于加强其所有部门的运营，并努力根据当前医疗保健行业开展新业务。除了满足人民的医疗保健要求外，这将使集团能够继续取得更好的成绩。
从长远角度来看，发马专注于通过提高制造和运营效率以及在研发方面取得进展来提高前景。这将使Pharmaniaga能够在马来西亚和海外市场利用新的机会，以确保发马在未来几年的可持续增长。
------------------------
James Ng Stock Pick Performance:
Since Recommended Return:
a. FRONTKEN CORP BHD, recommended on 12 Aug 18, initial price was RM0.715, rose to RM3.72, dividend RM0.04, in 2 years 15 days, total return is 425.9%
b. TOP GLOVE CORP BHD, recommended on 1 July 18, initial price was RM12.14, rose to RM52.80 adjusted, dividend RM0.52, in 2 Years 1 month 26 days, total return is 339.2%
c. MI TECHNOVATION BERHAD, recommended on 2 Jun 19, initial price was RM1.67, rose to RM6.56 adjusted, dividend RM0.055, in 1 Year 2 months 25 days, total return is 296.1%
d. OPENSYS M BHD, recommended on 24 May 20, initial price was RM0.355, rose to RM0.985, dividend RM0.0025, in 3 months 3 days, total return is 178.2%
e. KKB ENGINEERING BHD, recommended on 1 Jul 18, initial price was RM0.795, rose to RM1.60, dividend RM0.04, in 2 Years 1 month 26 days, total return is 106.3%
f. KAREX BHD, recommended on 20 Oct 19, initial price was RM0.445, rose to RM0.885, dividend RM0.015, in 10 months 7 days, total return is 102.2%
g. PERAK TRANSIT BHD, recommended on 19 Jul 20, initial price was RM0.18, rose to RM0.27, in 1 month 8 days, total return is 50%
h. MGB BHD, recommended on 1 March 20, initial price was RM0.565, rose to RM0.82, in 5 months 26 days , total return is 45.1%
i. PROLEXUS BHD, recommended on 25 Aug 19, initial price was RM0.455, rose to RM0.655, dividend RM0.003, in 1 Year 2 days, total return is 44.6%
j. DESTINI BHD, recommended on 24 Sep 19, initial price was RM0.20, rose to RM0.28, in 11 months 3 days, total return is 40%
我希望将我的策略分享给读者，希望他们在阅读后能够表现出色。我正在使用基本面分析Fundamental Analysis：
预计公司每年的增长率必须超过14％
我想说服读者学习基本面分析FA以便能从股市赚钱。
我为想从马来西亚股票市场赚钱的读者提供STOCK PICK服务。想订阅我的邮件以从股票市场获取良好回报的人，可以通过jamesngshare@gmail.com 或我的FB页面与我联系。
Whatsapp : 011 - 15852043
请订阅James的股票投资James Share Investing的Youtube频道：https://www.youtube.com/c/JamesShareInvesting
Facebook Group: https://www.facebook.com/groups/jamesinvesting
这个是我的TELEGRAM Group链接: https://t.me/joinchat/LhwHNhdU1fDgxrSafTrTiw
请大家来Follow James的Instagram，获取最新的资讯：jamesnginvest
免责声明：
高波动性投资产品，你的交易存在风险。过往表现不能作为将来业绩指标。内容仅作为分享，讨论以及领域的分析，而非是一种投资建议，买或卖自负。请Like和Share。最终决定永远是你的，谢谢。
James Ng
---------------------------
[PHARMANIAGA BHD: increased demand in the non-concession business, primarily as a result of higher sales of personal protective equipment due to the ongoing Covid-19 pandemic]
2Q20 vs 2Q19:
For the second quarter ended 30 June 2020, the Group delivered an improved revenue of RM646 million, up by 7.3% compared with RM602 million in the previous year’s corresponding quarter. This was driven by increased demand in the non-concession business, primarily as a result of higher sales of personal protective equipment due to the ongoing Covid-19 pandemic. As a result, the Group turned in a profit before zakat and taxation (PBT) of RM14 million, reflecting a growth of 14.8% compared with last year’s corresponding quarter. Accordingly, profit after tax (PAT) for the quarter under review grew by 3.7% to RM10 million, compared with RM9 million in the same quarter last year.
YTD20 vs YTD19:
For the first six months of the financial year under review, the Group delivered a higher revenue of RM1.5 billion compared with RM1.4 billion in the same period last year. This was achieved on the back of stronger contributions from the non-concession business, mainly due to higher sales of personal protective equipment in response to the Covid-19 outbreak. This saw the Group's PBT increase by 5.8% to RM45 million. As a result, the Group recorded a higher PAT of RM32 million compared with RM29 million in the same period last year.
The Logistics and Distribution Division turned in a higher PBT of RM37 million for the first six months, up by 96% compared with RM19 million in the same period last year. This was driven by improved contributions from the non-concession business.
The Manufacturing Division posted a PBT of RM13 million on the back of a revenue of RM137 million, in line with order trends from Government hospitals. The outlook remains positive for the Division, with new product launches in the pipeline. In addition, further expansion into overseas markets, as well as increased capacity utilisation via its contract manufacturing business will be pursued by the Group.
The Indonesia Division recorded a deficit of RM2 million.
2Q20 vs 1Q20:
PAT for the quarter under review stood at RM10 million, compared with RM22 million in the immediate preceding quarter.
Prospects:
Moving forward, the Group remains committed to strengthen operations across all its Divisions and endeavoring in new ventures in line with the current healthcare industry. Along with serving the healthcare requirements of the Rakyat, this will enable the Group to continue delivering better results.
Taking a longer-term perspective, the Group is focused on enhancing prospects by improving manufacturing and operational efficiencies, as well as progressing in its research and development efforts. This will allow Pharmaniaga to tap on new opportunities, both in Malaysia and overseas markets, to ensure the sustainable growth of the Group in the years ahead.
--------------------------------------------------------------------------
I wish to share my strategy to readers, hope that they can perform well after reading this. I am using Fundamental Analysis:
the forecasted growth of a company must over 14% per year
I wish to convince readers to learn FA in order to make money from stock market.
I am providing STOCK PICK SERVICE for readers who want to make money from Malaysian stock market. Those who want to subscribe to my mailing list to achieve a good return from stock market, you can contact me at jamesngshare@gmail.com or PM me in my FB page.
This sharing is purely a discussion and analysis of the sector, buying or selling at your own risk. Please Like and Share this post. Final decision is always yours, thank you.
James Ng
https://klse.i3investor.com/blogs/general/2020-08-28-story-h1512573411.jsp
2Q20 vs 2Q19:
截至2020年6月30日的第二季度，集团的收入增加到6.46亿令吉，比去年同期的6.02亿令吉增长7.3％。这主要是由于非特许业务的需求增加所致，这主要是由于持续的Covid-19大流行导致个人防护设备的销售增加所致。因此，集团取得了1,400万令吉的税前利润（PBT），与去年同期相比增长了14.8％。因此，这季的税后盈利（PAT）增长3.7％至1,000万令吉，相比去年同期的900万令吉。
YTD20 vs YTD19：
这财政年度的头六个月，集团实现了15亿令吉的收入，而去年同期为14亿令吉。这是在非特许经营业务的强劲贡献的支持下实现的，这主要是由于应对Covid-19疫情而导致的个人防护设备销量增加。这使集团的PBT增长5.8％至4,500万令吉。因此，集团录得3,200万令吉的PAT，高于去年同期的2,900万令吉。
物流及分销部首六个月的PBT为3,700万令吉，较去年同期的1,900万令吉增加96％。这是由于非特许业务的贡献有所提高。
制造部公布了1300万令吉的PBT，其营业额为1.37亿令吉，这与政府医院的订购趋势相符。随着新产品的推出，该部门的前景仍然乐观。此外，发马将寻求进一步拓展海外市场，以及通过其合同制造业务提高产能利用率。
印尼部门录得200万令吉的赤字。
2Q20 vs 1Q20：
这季度的PAT为1000万令吉，上一季度为2200万令吉。
前景：
展望未来，发马将继续致力于加强其所有部门的运营，并努力根据当前医疗保健行业开展新业务。除了满足人民的医疗保健要求外，这将使集团能够继续取得更好的成绩。
从长远角度来看，发马专注于通过提高制造和运营效率以及在研发方面取得进展来提高前景。这将使Pharmaniaga能够在马来西亚和海外市场利用新的机会，以确保发马在未来几年的可持续增长。
------------------------
James Ng Stock Pick Performance:
Since Recommended Return:
a. FRONTKEN CORP BHD, recommended on 12 Aug 18, initial price was RM0.715, rose to RM3.72, dividend RM0.04, in 2 years 15 days, total return is 425.9%
b. TOP GLOVE CORP BHD, recommended on 1 July 18, initial price was RM12.14, rose to RM52.80 adjusted, dividend RM0.52, in 2 Years 1 month 26 days, total return is 339.2%
c. MI TECHNOVATION BERHAD, recommended on 2 Jun 19, initial price was RM1.67, rose to RM6.56 adjusted, dividend RM0.055, in 1 Year 2 months 25 days, total return is 296.1%
d. OPENSYS M BHD, recommended on 24 May 20, initial price was RM0.355, rose to RM0.985, dividend RM0.0025, in 3 months 3 days, total return is 178.2%
e. KKB ENGINEERING BHD, recommended on 1 Jul 18, initial price was RM0.795, rose to RM1.60, dividend RM0.04, in 2 Years 1 month 26 days, total return is 106.3%
f. KAREX BHD, recommended on 20 Oct 19, initial price was RM0.445, rose to RM0.885, dividend RM0.015, in 10 months 7 days, total return is 102.2%
g. PERAK TRANSIT BHD, recommended on 19 Jul 20, initial price was RM0.18, rose to RM0.27, in 1 month 8 days, total return is 50%
h. MGB BHD, recommended on 1 March 20, initial price was RM0.565, rose to RM0.82, in 5 months 26 days , total return is 45.1%
i. PROLEXUS BHD, recommended on 25 Aug 19, initial price was RM0.455, rose to RM0.655, dividend RM0.003, in 1 Year 2 days, total return is 44.6%
j. DESTINI BHD, recommended on 24 Sep 19, initial price was RM0.20, rose to RM0.28, in 11 months 3 days, total return is 40%
我希望将我的策略分享给读者，希望他们在阅读后能够表现出色。我正在使用基本面分析Fundamental Analysis：
预计公司每年的增长率必须超过14％
我想说服读者学习基本面分析FA以便能从股市赚钱。
我为想从马来西亚股票市场赚钱的读者提供STOCK PICK服务。想订阅我的邮件以从股票市场获取良好回报的人，可以通过jamesngshare@gmail.com 或我的FB页面与我联系。
Whatsapp : 011 - 15852043
请订阅James的股票投资James Share Investing的Youtube频道：https://www.youtube.com/c/JamesShareInvesting
Facebook Group: https://www.facebook.com/groups/jamesinvesting
这个是我的TELEGRAM Group链接: https://t.me/joinchat/LhwHNhdU1fDgxrSafTrTiw
请大家来Follow James的Instagram，获取最新的资讯：jamesnginvest
免责声明：
高波动性投资产品，你的交易存在风险。过往表现不能作为将来业绩指标。内容仅作为分享，讨论以及领域的分析，而非是一种投资建议，买或卖自负。请Like和Share。最终决定永远是你的，谢谢。
James Ng
---------------------------
[PHARMANIAGA BHD: increased demand in the non-concession business, primarily as a result of higher sales of personal protective equipment due to the ongoing Covid-19 pandemic]
2Q20 vs 2Q19:
For the second quarter ended 30 June 2020, the Group delivered an improved revenue of RM646 million, up by 7.3% compared with RM602 million in the previous year’s corresponding quarter. This was driven by increased demand in the non-concession business, primarily as a result of higher sales of personal protective equipment due to the ongoing Covid-19 pandemic. As a result, the Group turned in a profit before zakat and taxation (PBT) of RM14 million, reflecting a growth of 14.8% compared with last year’s corresponding quarter. Accordingly, profit after tax (PAT) for the quarter under review grew by 3.7% to RM10 million, compared with RM9 million in the same quarter last year.
YTD20 vs YTD19:
For the first six months of the financial year under review, the Group delivered a higher revenue of RM1.5 billion compared with RM1.4 billion in the same period last year. This was achieved on the back of stronger contributions from the non-concession business, mainly due to higher sales of personal protective equipment in response to the Covid-19 outbreak. This saw the Group's PBT increase by 5.8% to RM45 million. As a result, the Group recorded a higher PAT of RM32 million compared with RM29 million in the same period last year.
The Logistics and Distribution Division turned in a higher PBT of RM37 million for the first six months, up by 96% compared with RM19 million in the same period last year. This was driven by improved contributions from the non-concession business.
The Manufacturing Division posted a PBT of RM13 million on the back of a revenue of RM137 million, in line with order trends from Government hospitals. The outlook remains positive for the Division, with new product launches in the pipeline. In addition, further expansion into overseas markets, as well as increased capacity utilisation via its contract manufacturing business will be pursued by the Group.
The Indonesia Division recorded a deficit of RM2 million.
2Q20 vs 1Q20:
PAT for the quarter under review stood at RM10 million, compared with RM22 million in the immediate preceding quarter.
Prospects:
Moving forward, the Group remains committed to strengthen operations across all its Divisions and endeavoring in new ventures in line with the current healthcare industry. Along with serving the healthcare requirements of the Rakyat, this will enable the Group to continue delivering better results.
Taking a longer-term perspective, the Group is focused on enhancing prospects by improving manufacturing and operational efficiencies, as well as progressing in its research and development efforts. This will allow Pharmaniaga to tap on new opportunities, both in Malaysia and overseas markets, to ensure the sustainable growth of the Group in the years ahead.
--------------------------------------------------------------------------
I wish to share my strategy to readers, hope that they can perform well after reading this. I am using Fundamental Analysis:
the forecasted growth of a company must over 14% per year
I wish to convince readers to learn FA in order to make money from stock market.
I am providing STOCK PICK SERVICE for readers who want to make money from Malaysian stock market. Those who want to subscribe to my mailing list to achieve a good return from stock market, you can contact me at jamesngshare@gmail.com or PM me in my FB page.
This sharing is purely a discussion and analysis of the sector, buying or selling at your own risk. Please Like and Share this post. Final decision is always yours, thank you.
James Ng
https://klse.i3investor.com/blogs/general/2020-08-28-story-h1512573411.jsp
